Obesity Drug Updates: Wegovy Price Drop, Mounjaro Expansion & New Weight-Loss Treatments
The obesity treatment landscape is evolving rapidly! In this week’s update, we cover groundbreaking developments in obesity and weight-loss medications, including:
🔹 Novo Nordisk launches NovoCare® Pharmacy, cutting Wegovy® prices to $499/month
🔹 VIVUS introduces QSYMIA® in the UAE, addressing rising obesity rates1
🔹 Eli Lilly expands Mounjaro to China, India, Brazil, and Mexico by 2026
🔹 Hikma prepares for generic semaglutide, potentially slashing prices by 80-85%
🔹 Novo Nordisk’s CagriSema Shows Strong Weight-Loss Results
🔹 Arrowhead’s RNAi-based obesity treatments show promise for 50% fat reduction
🔹 Amgen’s MariTide enters Phase 3 trials, with 20% weight-loss potential Stay informed on the latest breakthroughs in obesity treatment, clinical trials, and regulatory updates!
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on obesity and weight-loss treatments
#ObesityTreatment #WeightLossDrugs #Wegovy #Mounjaro #Semaglutide #ClinicalTrials #PharmaNews #LucidQuest